

Sigrun Halvorsen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1226469/sigrun-halvorsen-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152
papers

23,671
citations

39
h-index

153
g-index

172
ext. papers

33,611
ext. citations

6.1
avg, IF

5.77
L-index

#	Paper	IF	Citations
152	A nationwide registry study on heart failure in Norway from 2008 to 2018: variations in lookback period affect incidence estimates.. <i>BMC Cardiovascular Disorders</i> , 2022 , 22, 88	2.3	0
151	Performance of the Novel Observation Group Criteria of the European Society of Cardiology (ESC) 0/1-Hour Algorithm in a Low-Risk Population.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024927	6.9	0
150	Coagulation factors XI and XII as possible targets for anticoagulant therapy.. <i>Thrombosis Research</i> , 2022 , 214, 53-62	8.2	0
149	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2021 ,	9.9	3
148	Diagnostic Accuracy and Usability of the ECG247 Smart Heart Sensor Compared to Conventional Holter Technology. <i>Journal of Healthcare Engineering</i> , 2021 , 2021, 5230947	3.7	2
147	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute Cardiovascular Care and the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 343-355	4.3	4
146	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021 , 44, 1219-1227	14.6	9
145	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2021 , 143, 1215-1223	16.7	1
144	Comparison of management and outcomes of ST-segment elevation myocardial infarction patients in Estonia, Hungary, Norway and Sweden according to national ongoing registries. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	1
143	Differences in characteristics, treatments and outcomes in patients with non-ST-elevation myocardial infarction -novel insights from four national European continuous real-world registries. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	1
142	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 768-780	5	2
141	Outcomes after delayed primary percutaneous coronary intervention versus pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	1
140	Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation. <i>Heart</i> , 2021 ,	5.1	4
139	Impact of Preinjury Antithrombotic Therapy on 30-Day Mortality in Older Patients Hospitalized With Traumatic Brain Injury (TBI). <i>Frontiers in Neurology</i> , 2021 , 12, 650695	4.1	2
138	Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 570-583	4.3	9
137	Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns. <i>Clinical Therapeutics</i> , 2021 , 43, 1179-1190.e3	3.5	0
136	Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal: Cardiovascular Pharmacotherapy</i> , 2021 , 7, 125-140	6.4	16

135	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021 , 42, 1289-1367	9.5	920
134	2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTEMI-ACS guideline group. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 224-233	4.3	15
133	Comparison of a single high-sensitivity cardiac troponin T measurement with the HEART score for rapid rule-out of acute myocardial infarction in a primary care emergency setting: a cohort study. <i>BMJ Open</i> , 2021 , 11, e046024	3	1
132	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021 , 42, 3227-3337	9.5	358
131	Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute Cardiovascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 947-959	4.3	5
130	Rifaximin or <i>Saccharomyces boulardii</i> in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. <i>EBioMedicine</i> , 2021 , 70, 103511	8.8	7
129	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 421-433	15.1	13
128	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. <i>European Heart Journal</i> , 2020 , 41, 1839-1851	9.5	76
127	Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016. <i>ESC Heart Failure</i> , 2020 , 7, 1917-1926	3.7	5
126	Prevalence of genetically verified familial hypercholesterolemia among young (. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 339-345	4.9	2
125	Double-Stranded DNA and NETs Components in Relation to Clinical Outcome After ST-Elevation Myocardial Infarction. <i>Scientific Reports</i> , 2020 , 10, 5007	4.9	5
124	Eivind Berge, MD, PhD, 1964-2020: Cardiologist Who Was Fighting Stroke. <i>Stroke</i> , 2020 , 51, 1353-1355	6.7	1
123	Worst lead ST deviation and resolution of ST elevation at one hour for prediction of myocardial salvage, infarct size, and microvascular obstruction in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. <i>Annals of Noninvasive Electrocardiology</i> , 2020 , 25, e12784	1.5	2
122	Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 348-357	4.3	16
121	Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 75-85	6.4	28
120	Diagnosis and risk stratification of chest pain patients in the emergency department: focus on acute coronary syndromes. A position paper of the Acute Cardiovascular Care Association. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 76-89	4.3	34
119	Incidence, risk factors and outcome of young patients with myocardial infarction. <i>Heart</i> , 2020 , 106, 1420-1426	5.14	14
118	Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2020 , 221, 1-8	4.9	10

117	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 133-144	15.1	147
116	Pre-hospital One-Hour Troponin in a Low-Prevalence Population of Acute Coronary Syndrome: OUT-ACS study. <i>Open Heart</i> , 2020 , 7,	3	3
115	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020 , 41, 4245-4255	9.5	44
114	Music therapy as an adjunct in cardiac device lead extraction procedures: A randomized controlled trial. <i>Applied Nursing Research</i> , 2020 , 56, 151376	1.8	3
113	Incidence and prevalence of venous thromboembolism in Norway 2010-2017. <i>Thrombosis Research</i> , 2020 , 195, 165-168	8.2	4
112	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 407-477	9.5	1835
111	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020 , 41, 111-188	9.5	2236
110	2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020 , 41, 655-720	9.5	267
109	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020 , 41, 255-323	9.5	1360
108	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020 , 41, 543-603	9.5	1043
107	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2019 , 140, 1921-1932	16.7	40
106	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019 , 218, 57-65	4.9	3
105	Long-term cardiovascular morbidity following hyperemesis gravidarum: A Norwegian nationwide cohort study. <i>PLoS ONE</i> , 2019 , 14, e0218051	3.7	1
104	"Doctor, Should I Keep Taking an Aspirin a Day?". <i>New England Journal of Medicine</i> , 2019 , 380, 1967-1970	59.2	14
103	Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 1373-1382	3.9	9
102	Facilitated music listening: Music therapy in an invasive cardiac procedure. <i>British Journal of Music Therapy</i> , 2019 , 33, 27-38	0.6	2
101	Unsatisfactory risk factor control and high rate of new cardiovascular events in patients with myocardial infarction and prior coronary artery disease. <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 71	2.3	10
100	Fourth universal definition of myocardial infarction (2018).. <i>European Heart Journal</i> , 2019 , 40, 237-269	9.5	851

99	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society. <i>Europace</i> , 2019 , <i>21</i> , 192-193	3.9	155
98	Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: Understanding and addressing the global risk-treatment paradox. <i>Clinical Cardiology</i> , 2019 , <i>42</i> , 1028-1040	3.3	9
97	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , <i>7</i> , 618-628	18.1	120
96	Long-Term Survival after Invasive or Conservative Strategy in Elderly Patients with non-ST-Elevation Myocardial Infarction: A Prospective Cohort Study. <i>Cardiology</i> , 2019 , <i>144</i> , 79-89	1.6	2
95	Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. <i>BMC Medicine</i> , 2019 , <i>17</i> , 198	11.4	39
94	Experiences of informal caregivers after cardiac surgery: a systematic integrated review of qualitative and quantitative studies. <i>BMJ Open</i> , 2019 , <i>9</i> , e032751	3	4
93	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. <i>Heart</i> , 2019 , <i>105</i> , 235-242	5.1	11
92	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2019 , <i>208</i> , 123-131	4.9	35
91	BETablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. <i>American Heart Journal</i> , 2019 , <i>208</i> , 37-46	4.9	10
90	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018 , <i>39</i> , 1672-1686f	9.5	59
89	Correlation of anteroseptal ST elevation with myocardial infarction territories through cardiovascular magnetic resonance imaging. <i>Journal of Electrocardiology</i> , 2018 , <i>51</i> , 563-568	1.4	4
88	Cardiovascular risk profile at the age of 40-45 in women with previous hyperemesis gravidarum or hypertensive disorders in pregnancy: A population-based study. <i>Pregnancy Hypertension</i> , 2018 , <i>12</i> , 129-135	2.6	6
87	Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. <i>Journal of the American Heart Association</i> , 2018 , <i>7</i> ,	6	28
86	Longitudinal left ventricular function is globally depressed within a week of STEMI. <i>Clinical Physiology and Functional Imaging</i> , 2018 , <i>38</i> , 1029	2.4	6
85	Markers of Thrombin Generation Are Associated With Long-Term Clinical Outcome in Patients With ST-Segment Elevation Myocardial Infarction. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , <i>24</i> , 1088-1094	3.3	6
84	Correlation of ST changes in leads V4-V6 to area of ischemia by CMR in inferior STEMI. <i>Scandinavian Cardiovascular Journal</i> , 2018 , <i>52</i> , 189-195	2	1
83	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2018 , <i>39</i> , 119-177	9.5	4237
82	Appropriateness of anteroseptal myocardial infarction nomenclature evaluated by late gadolinium enhancement cardiovascular magnetic resonance imaging. <i>Journal of Electrocardiology</i> , 2018 , <i>51</i> , 218-223	1.4	1

81	The significance of ST-elevation in aVL in anterolateral myocardial infarction: An assessment by cardiac magnetic resonance imaging. <i>Annals of Noninvasive Electrocardiology</i> , 2018 , 23, e12580	1.5	7
80	Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Practical perspectives based on data from the TREAT study. <i>Clinical Cardiology</i> , 2018 , 41, 1322-1327 ⁶	3.3	6
79	Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial. <i>ESC Heart Failure</i> , 2018 , 5, 977-984	3.7	25
78	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2018 , 197, 133-141	4.9	16
77	Long-term survival in patients with acute myocardial infarction and out-of-hospital cardiac arrest: A prospective cohort study. <i>Resuscitation</i> , 2018 , 122, 41-47	4	20
76	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. <i>Open Heart</i> , 2018 , 5, e000908	3	4
75	Cardiac Magnetic Resonance Evaluation of the Extent of Myocardial Injury in Patients with Inferior ST Elevation Myocardial Infarction and Concomitant ST Depression in Leads V1-V3: Analysis from the MITOCARE Study. <i>Cardiology</i> , 2018 , 140, 178-185	1.6	6
74	Diagnosing heart failure with NT-proBNP point-of-care testing: lower costs and better outcomes. A decision analytic study. <i>BJGP Open</i> , 2018 , 2, bjgpopen18X101596	3.1	7
73	New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs. <i>Open Heart</i> , 2018 , 5, e000931	3	9
72	Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force. <i>European Heart Journal</i> , 2018 , 39, 4239-4242	9.5	18
71	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). <i>Circulation</i> , 2017 , 136, 1193-1203	16.7	33
70	Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 61-70	3.9	16
69	Monocyte-derived circulating microparticles (CD14, CD14/CD11b and CD14/CD142) are related to long-term prognosis for cardiovascular mortality in STEMI patients. <i>International Journal of Cardiology</i> , 2017 , 227, 876-881	3.2	36
68	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1760-1776	15.1	100
67	Evaluation of circulating levels of CCN2/connective tissue growth factor in patients with ST-elevation myocardial infarction. <i>Scientific Reports</i> , 2017 , 7, 11945	4.9	3
66	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017 , 38, 1455-1462	9.5	63
65	Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis. <i>American Heart Journal</i> , 2017 , 193, 46-54	4.9	1
64	Geographical differences in prescription of secondary preventive drug therapy after acute myocardial infarction in Norway. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 132-133 ⁶	6.4	4

63	Gender differences in all-cause, cardiovascular and cancer mortality during long-term follow-up after acute myocardial infarction; a prospective cohort study. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 75	2.3	14
62	A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 28-36	6.4	75
61	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (LACEP). <i>Europace</i> , 2017 , 19, 1757-1758	3.9	75
60	Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 673-81	16.2	59
59	Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 115	2.3	34
58	Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction. <i>Heart</i> , 2016 , 102, 527-33	5.1	4
57	Long-term survival in octogenarians and older patients with ST-elevation myocardial infarction in the era of primary angioplasty: A prospective cohort study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 243-52	4.3	17
56	Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 685-711	7	21
55	Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint. <i>Journal of the American Heart Association</i> , 2016 , 5, e002708	6	27
54	Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STRategic Reperfusion Early After Myocardial Infarction (STREAM) Study. <i>Journal of the American Heart Association</i> , 2016 , 5, e002708	6	5
53	Radial versus femoral access for percutaneous coronary intervention in ST-elevation myocardial infarction patients treated with fibrinolysis: Results from the randomized routine early invasive clinical trials. <i>Cardiovascular Revascularization Medicine</i> , 2016 , 17, 295-301	1.6	2
52	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 126-35	16.2	161
51	The Obesity Paradox in Atrial Fibrillation: Observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. <i>European Heart Journal</i> , 2016 , 37, 2869-2878	9.5	144
50	Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	38
49	Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. <i>Heart</i> , 2015 , 101, 1554-61	5.1	7
48	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015 , 36, 3238-49	9.5	129
47	Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. <i>Heart</i> , 2015 , 101, 692-8	3.1	16
46	Design and rationale of TROCADERO: A TRIAL Of Caffeine to Alleviate Dyspnea Related to ticagrelor. <i>American Heart Journal</i> , 2015 , 170, 465-70	4.9	7

45	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRs). <i>Europace</i> , 2015 , 17, 1197-214	3.9	123
44	Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. <i>European Heart Journal</i> , 2015 , 36, 112-9	9.5	129
43	Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction?. <i>Journal of the American Heart Association</i> , 2015 , 4, e002049	6	10
42	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	46
41	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015 , 36, 3268-75	9.5	30
40	Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trials. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 166-174	5	27
39	Networks for improving care in patients with acute coronary syndrome: A framework. <i>Acute Cardiac Care</i> , 2014 , 16, 41-8		2
38	Routine invasive management early after fibrinolysis: relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials. <i>American Heart Journal</i> , 2014 , 168, 757-65	4.9	4
37	ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. <i>Circulation</i> , 2014 , 130, 1139-45	16.7	58
36	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular	9.5	413
35	Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 319-27	15.1	123
34	IL-6 signalling in patients with acute ST-elevation myocardial infarction. <i>Results in Immunology</i> , 2014 , 4, 8-13		40
33	Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process. <i>Chest</i> , 2014 , 146, 727-734	5.3	13
32	Prevalence of risk factors at presentation and early mortality in patients aged 80 years or older with ST-segment elevation myocardial infarction. <i>Vascular Health and Risk Management</i> , 2014 , 10, 683-9	4.4	9
31	Health-related quality of life after myocardial infarction, does choice of method make a difference?. <i>Scandinavian Cardiovascular Journal</i> , 2014 , 48, 216-22	2	3
30	Applying new strategies for the national adaptation, updating, and dissemination of trustworthy guidelines: results from the Norwegian adaptation of the Antithrombotic Therapy and the Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2014 , 146, 735-761	5.3	28
29	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014 , 35, 1864-72	9.5	237
28	Myocardial infarction in Norway in 2013. <i>Tidsskrift for Den Norske Laegeforening</i> , 2014 , 134, 1841-6	3.5	15

27	Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. <i>New England Journal of Medicine</i> , 2013 , 368, 1379-87	59.2	448
26	Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?. <i>European Heart Journal</i> , 2013 , 34, 1630-5	9.5	36
25	Inflammatory and thrombotic markers in patients with ST-elevation myocardial infarction treated with thrombolysis and early PCI: a NORDISTEMI substudy. <i>Thrombosis Research</i> , 2012 , 130, 495-500	8.2	15
24	Ethnicity and acute myocardial infarction: risk profile at presentation, access to hospital management, and outcome in Norway. <i>Vascular Health and Risk Management</i> , 2012 , 8, 505-15	4.4	6
23	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012 , 33, 2569-619	9.5	3978
22	STEMI treatment in areas remote from primary PCI centres. <i>EuroIntervention</i> , 2012 , 8 Suppl P, P44-50	3.1	2
21	Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels 3 months after myocardial infarction are more strongly associated with magnetic resonance-determined ejection fraction than NTproBNP levels in the acute phase. <i>Journal of Cardiac Failure</i> , 2011 , 17, 479-86	3.3	7
20	The role of beta-blockers in the treatment of chronic heart failure. <i>Trends in Pharmacological Sciences</i> , 2011 , 32, 206-12	13.2	22
19	The role of fibrinolysis in the era of primary percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 390-5	7	12
18	Assessment of left ventricular function in ST-elevation myocardial infarction by global longitudinal strain: a comparison with ejection fraction, infarct size, and wall motion score index measured by non-invasive imaging modalities. <i>European Journal of Echocardiography</i> , 2011 , 12, 678-83		21
17	Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. <i>European Heart Journal</i> , 2010 , 31, 2156-69	9.5	129
16	Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on District treatment of ST-elevation myocardial infarction). <i>Journal of the American College of Cardiology</i> , 2010 , 55, 100-10	15.1	170
15	Left ventricular function in acute myocardial infarction treated with thrombolysis followed by early versus late invasive strategy. <i>American Heart Journal</i> , 2010 , 160, 73-9	4.9	7
14	The association between metabolic syndrome and infarct size in patients with acute myocardial infarction. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010 , 70, 287-93	2	6
13	Gender differences in management and outcome of acute myocardial infarctions treated in 2006-2007. <i>Cardiology</i> , 2009 , 114, 83-8	1.6	39
12	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. <i>European Heart Journal</i> , 2008 , 29, 2909-45	9.5	1774
11	The NORwegian study on DIstrict treatment of ST-elevation myocardial infarction (NORDISTEMI). <i>Scandinavian Cardiovascular Journal</i> , 2007 , 41, 32-8	2	13
10	Myocardial perfusion in ST-elevation myocardial infarction treated successfully with primary angioplasty. <i>Scandinavian Cardiovascular Journal</i> , 2006 , 40, 96-104	2	10

9	Cost-effectiveness of primary percutaneous coronary intervention versus thrombolytic therapy for acute myocardial infarction. <i>Scandinavian Cardiovascular Journal</i> , 2005 , 39, 276-85	2	25
8	The viscosity of fibrinogen subfractions and of EDTA denatured fibrinogen do not differ from that of native fibrinogen. <i>Thrombosis Research</i> , 2004 , 113, 51-6	8.2	3
7	Influence of freeze-drying on the clotting properties of fibrinogen in plasma. <i>Thrombosis Research</i> , 2002 , 105, 499-502	8.2	9
6	Discrepancy between fibrinogen concentrations determined by clotting rate and clottability assays during the acute-phase reaction. <i>Thrombosis Research</i> , 2000 , 100, 397-403	8.2	20
5	D-dimers are degraded by human neutrophil elastase. <i>Thrombosis Research</i> , 1996 , 82, 177-86	8.2	15
4	Impaired clot lysis in the presence of human neutrophil elastase. <i>Thrombosis Research</i> , 1995 , 80, 153-9	8.2	7
3	Impaired coagulation of fibrinogen due to digestion of the C-terminal end of the A alpha-chain by human neutrophil elastase. <i>Thrombosis Research</i> , 1994 , 73, 61-8	8.2	18
2	Degradation of the alpha-chain of fibrin by human neutrophil elastase reduces the stimulating effect of fibrin on plasminogen activation. <i>Thrombosis Research</i> , 1994 , 75, 307-17	8.2	17
1	The cardiac arrest centre for the treatment of sudden cardiac arrest due to presumed cardiac cause: aims, function, and structure: position paper of the ACVC association of the ESC, EAPCI, EHRA, ERC, EUSEM, and ESICM. <i>European Heart Journal: Acute Cardiovascular Care</i> ,	4.3	3